View ValuationOramed Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Oramed Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 17Oramed Pharmaceuticals Inc. announced delayed 10-Q filingOn 05/15/2026, Oramed Pharmaceuticals Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Mar 29New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 189% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (189% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (US$2.0m revenue).お知らせ • Mar 26Lifeward Ltd. (NasdaqCM:LFWD) completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP).Lifeward Ltd. (NasdaqCM:LFWD) entered into a share purchase agreement to acquire Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) on January 12, 2026. At closing, the Company will issue ordinary shares and pre-funded warrants to Oramed Pharmaceuticals, Inc. in an amount representing 49.99% of the Company’s fully diluted equity capitalization, subject to certain adjustments and ownership limitations. The number of ordinary shares issued at closing is capped at 45% of Lifeward’s outstanding ordinary shares, with the balance issued in the form of pre-funded warrants. Approximately 5% of the equity consideration will be held back in the form of pre-funded warrants for indemnification purposes and released after 12 months, subject to claims. In addition, the Company will issue transaction warrants to purchase ordinary shares, with the number of warrants determined by dividing Lifeward’s net cash at closing by an exercise price of $0.45 per share. As further consideration, Lifeward agreed to make contingent quarterly revenue-sharing payments equal to 4% of net revenue from sales of ReWalk Personal Exoskeleton products and related warranties. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, registration statement effectiveness (S-4 / F-4), lock-up agreement and listing / approval of new shares on stock exchange. The transaction has received unanimous approval from Lifeward’s board of directors. The transaction is contingent upon closing conditions. As of March 12, 2026, Lifeward Ltd. shareholders approved the transaction. Rachael M. Bushey and Jennifer Porter of Goodwin Procter LLP acted as legal advisor for Lifeward Ltd. Aaron M. Lampert and Ephraim P. Friedman of Goldfarb Seligman & Co. acted as legal advisor for Lifeward Ltd. Rick A. Werner, Alla Digilova, and Simin Sun of Haynes and Boone, LLP acted as legal advisor for Oramed Pharmaceuticals Inc. Lifeward Ltd. (NasdaqCM:LFWD) completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) on March 25, 2026. At closing, Lifeward issued an aggregate 2,256,476 shares of its ordinary shares and pre-funded warrants. Lifeward also issued 1,296,296 warrants to purchase Oratech Pharma's ordinary shares.Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₪10.58, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 19% over the past three years.お知らせ • Jan 08Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026Oramed Pharmaceuticals Inc.'s Board of Directors approved a cash dividend payment of $0.25 per share. The dividend will have an ex-dividend date of January 16, 2026, with disbursement scheduled for January 26, 2026. The dividend is expected to result in an aggregate distribution of approximately $10.5 million based on the current number of shares outstanding. The dividend will be funded with surplus capital.お知らせ • Jan 01Oramed Pharmaceuticals Inc. Announces Resignation of Leonard Sank from the Board, Effective as of January 1, 2026On December 31, 2025, the board of directors (the “Board”) of Oramed Pharmaceuticals Inc. (the “Company”) received notice of Leonard Sank’s intention to resign from the Board, effective as of January 1, 2026. Mr. Sank’s resignation did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Sank served 18 years at the Company.Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₪10.33, the stock trades at a trailing P/E ratio of 2.8x. Average forward P/E is 20x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 62% over the past three years.New Risk • Nov 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (135% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (₪324.5m market cap, or US$99.1m).お知らせ • Nov 18Oramed Pharmaceuticals Inc. Declares Dividend Distribution of Common Stock, Payable on November 27, 2025The Board of Directors of Oramed Pharmaceuticals Inc. announced that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company. The dividend distribution will be payable on November 27, 2025, to stockholders of record as of the close of business on November 27, 2025.お知らせ • Jul 17Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 19, 2025Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 19, 2025. Location: proskauer rose llp, one boca place, 2255 glades road, suite 421 atrium, fl 33431-7360, boca raton United StatesBoard Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Member of Scientific Advisory Board Anne Peters was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • Apr 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$2.8m net loss next year). Market cap is less than US$100m (₪321.2m market cap, or US$85.8m).New Risk • Mar 29New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$19m Forecast net loss in 1 year: US$4.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$4.7m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₪329.4m market cap, or US$89.1m).Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₪9.16, the stock trades at a trailing P/E ratio of 23.2x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 69% over the past three years.New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 104% per year for the foreseeable future. High level of non-cash earnings (40% accrual ratio). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (5.8% average weekly change).Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₪9.34, the stock trades at a trailing P/E ratio of 23.5x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 75% over the past three years.New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 188% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings are forecast to decline by an average of 198% per year for the foreseeable future. High level of non-cash earnings (188% accrual ratio). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪348.7m market cap, or US$95.1m).New Risk • Jul 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪371.5m (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings are forecast to decline by an average of 169% per year for the foreseeable future. Revenue is less than US$1m (US$674k revenue). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₪371.5m market cap, or US$98.7m).Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₪9.79, the stock trades at a trailing P/E ratio of 10x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 77% over the past three years.お知らせ • Jun 27Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its shares. The program will expired in 12 months.お知らせ • Jun 22Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024. Location: 20 mamilla avenue, israel 9414904, jerusalem Israelお知らせ • Jun 13+ 1 more updateOramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024On June 6, 2024, Oramed Pharmaceuticals Inc. appointed Mr. Avraham Gabay to serve as Treasurer and Secretary of the Company, effective as of June 18, 2024. Prior to his appointment, Mr. Gabay served as interim chief financial officer of BiomX Inc. since 2023. From 2021 until 2023, Mr. Gabay served as the chief financial officer at Oravax Inc., a 63% owned subsidiary of the Company. From 2019 until 2021, Mr. Gabay was the chief financial officer of the Company. From 2015 to 2019, Mr. Gabay served as VP Finance at Orcam Technologies Ltd. From 2014 to 2015, Mr. Gabay provided economic services in the advisory department of KPMG Israel, a certified public accounting firm, and from 2013 to 2014, he worked in the tax department of the law firm Gornitzky & Co. In addition, Mr. Gabay serves as a director on the board of Iintoo Ltd. Mr. Gabay holds a bachelor’s degree in law and accounting (magna cum-laude) from Tel-Aviv University and is a certified public accountant in Israel and a member of the Israeli Bar Association.New Risk • May 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 95% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings are forecast to decline by an average of 95% per year for the foreseeable future. Revenue is less than US$1m (US$674k revenue). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₪345.9m market cap, or US$93.4m).Reported Earnings • May 12First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)First quarter 2024 results: EPS: US$0.038 (up from US$0.085 loss in 1Q 2023). Net income: US$1.54m (up US$4.93m from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.New Risk • Apr 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪369.9m (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (US$1.3m revenue). Market cap is less than US$100m (₪369.9m market cap, or US$98.1m).お知らせ • Mar 19Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: COMMON STOCK Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Mar 07Full year 2023 earnings released: EPS: US$0.14 (vs US$0.94 loss in FY 2022)Full year 2023 results: EPS: US$0.14 (up from US$0.94 loss in FY 2022). Net income: US$5.53m (up US$42.1m from FY 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.New Risk • Jan 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.2% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$11m net loss next year). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Revenue is less than US$5m (US$2.0m revenue).Board Change • Jan 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 5 highly experienced directors. Member of Scientific Advisory Board Jay Skyler was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Dec 19Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024On December 18, 2023, Oramed Pharmaceuticals Inc. (Company) increased the size of its Board of Directors by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024. The Board has not yet taken action to appoint Dr. Aghion to any committees of the Board. Dr. Daniel Aghion, age 42, is a neurosurgeon at Memorial Neuroscience Institute in Florida since 2016, where he treats patients with a wide array of spine disorders, including severe degenerative spine diseases, spine trauma, cancer in the spine, spine tumors, peripheral nerve surgery and more. Dr. Aghion holds a Bachelor's of Science degree from the University of Michigan and an MD from the Sackler School of Medicine at Tel Aviv University. He completed his residency at Rhode Island Hospital in 2015, and a complex spine fellowship at Johns Hopkins University in Baltimore in 2016.Reported Earnings • Nov 11Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)Third quarter 2023 results: US$0.08 loss per share (improved from US$0.18 loss in 3Q 2022). Net loss: US$3.22m (loss narrowed 54% from 3Q 2022). Revenue is expected to decline by 70% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Asia are expected to grow by 11%. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.New Risk • Oct 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪357.4m (US$93.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$47m net loss in 3 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Revenue is less than US$5m (US$2.7m revenue). Market cap is less than US$100m (₪357.4m market cap, or US$93.0m).Reported Earnings • Aug 11Second quarter 2023 earnings released: US$0.03 loss per share (vs US$0.27 loss in 2Q 2022)Second quarter 2023 results: US$0.03 loss per share (improved from US$0.27 loss in 2Q 2022). Net loss: US$1.19m (loss narrowed 89% from 2Q 2022). Revenue is expected to decline by 84% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Asia are expected to grow by 9.8%. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.お知らせ • Aug 09Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million on August 4, 2023. Oramed Pharmaceuticals Inc. entered into a Stalking Horse Agreement to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. on August 8, 2023. Oramed to purchase 59,726,737 shares of common stock of Scilex and 29,057,096 shares of Series A preferred stock of Scilex under the transaction. As a part of consideration, Oramed will provide a non-amortizing super-priority debtor-in-possession term loan financing facility in an aggregate principal amount of $100 million (the “Replacement DIP Facility”) and remaining consideration in cash. Oramed Pharmaceuticals Inc. will receive a a break-up fee in the amount of $3,412,500, in case of termmination. Oramed will be capitalized with sufficient debt and equity capital to fund the cash portion of the Purchase Price. Term Sheet is subject to a final definitive documentation to be negotiated in good faith between the parties, uthorization and approval by the United States Bankruptcy Court for the Southern District of Texas,all HSR filing and waiting periods applicable to the Sale shall have expired or been terminated, all other governmental and regulatory approvals, if any, shall have been obtained, parties shall have entered into a new Registration Rights Agreement, approval of board of directors of Scilex and satisfaction or waiver of the other Closing Conditions. The proposed transaction will not be subject to a financing contingency. The stalking horse agreement with Oramed is subject to an auction and the submission of higher or otherwise better offers. Any parties interested in bidding for the Scilex Stock should email Sorrento's investment banker (Moelis & Company LLC) as soon as possible to indicate their interest and discuss required bid materials. To the extent Sorrento receives any qualified bids that are higher or otherwise better than Oramed's bid by August 11, 2023, at 5:00 p.m. (ET), Sorrento will hold an auction for the Scilex Stock on August 14, 2023. The U.S. Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") approved the transaction on August 8, 2023. Transaction is expected to be completed by or before September 15, 2023. Latham & Watkins LLP and Jackson Walker LLP are serving as legal counsel to Sorrento. M3 Partners is serving as restructuring advisor. Moelis & Company LLC is serving as financial advisor and investment banker. H.C. Wainwright & Co. acted as financial and capital markets advisor to Oramed.お知らせ • Jul 12Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023, at 16:00 Israel Standard Time. Location: 20 Mamilla Avenue Jerusalem Israel Agenda: To consider and re-elect six directors of the Company to hold office until next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal; to consider and ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited as the independent registered public accounting firm of the Company for the 2023 fiscal year; and to transact any other business as may properly come before the Annual Meeting or any adjournments thereof.Reported Earnings • May 13First quarter 2023 earnings released: US$0.085 loss per share (vs US$0.27 loss in 1Q 2022)First quarter 2023 results: US$0.085 loss per share (improved from US$0.27 loss in 1Q 2022). Net loss: US$3.40m (loss narrowed 67% from 1Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Apr 06Independent Director recently bought ₪70k worth of stockOn the 4th of April, Arie Mayer bought around 9k shares on-market at roughly ₪7.94 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₪729k. Insiders have collectively bought ₪406k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Mar 16Independent Director recently bought ₪513k worth of stockOn the 14th of March, Yadin Rozov bought around 70k shares on-market at roughly ₪7.33 per share. This transaction increased Yadin's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₪211k more in shares than they have sold in the last 12 months.Reported Earnings • Mar 08Full year 2022 earnings released: US$0.94 loss per share (vs US$0.94 loss in FY 2021)Full year 2022 results: US$0.94 loss per share. Net loss: US$36.6m (loss widened 4.4% from FY 2021). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.お知らせ • Jan 12Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 DiabetesOramed Pharmaceuticals Inc. announced top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents. The ORA-D-013-1 trial did not meet its primary endpoint, which compared the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by the mean change from baseline in A1C at 26 weeks. The trial also did not meet its secondary endpoint, which assessed the mean change from baseline in fasting plasma glucose at 26 weeks. There were no serious drug-related adverse events. Therefore, Oramed expects to discontinue its oral insulin clinical activities for T2D. Additional Information About the ORA-D-013-1 Phase 3 Clinical Trial: In the ORA-D-013-1 trial, patients were randomized 2:2:1:1 into four groups: 8 mg dosed once-daily; 8 mg dosed twice-daily; placebo dosed once-daily; and placebo dosed twice-daily. Patients completed an initial 21-day Screening Period, followed by a 26-week Double-Blind Treatment Period.お知らせ • Jan 05Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of DiabetesOramed Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Chief Scientific Officer & Director Miriam Kidron is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 12Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)Third quarter 2022 results: US$0.18 loss per share. Net loss: US$7.06m (loss widened 3.0% from 3Q 2021). Revenue is forecast to grow 86% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia.Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 2Q 2021)Second quarter 2022 results: US$0.27 loss per share (down from US$0.17 loss in 2Q 2021). Net loss: US$10.5m (loss widened 102% from 2Q 2021). Over the next year, revenue is forecast to grow 6.4%, compared to a 24% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.Board Change • Jul 15High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Chief Scientific Officer & Director Miriam Kidron is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • May 14First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 1Q 2021)First quarter 2022 results: US$0.27 loss per share (down from US$0.17 loss in 1Q 2021). Net loss: US$10.4m (loss widened 126% from 1Q 2021). Over the next year, revenue is forecast to grow 2.5%, compared to a 23% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Reported Earnings • Apr 02Full year 2021 earnings released: US$0.94 loss per share (vs US$0.90 loss in FY 2020)Full year 2021 results: US$0.94 loss per share (down from US$0.90 loss in FY 2020). Net loss: US$35.0m (loss widened 59% from FY 2020). Over the next year, revenue is forecast to grow 1.4%, compared to a 21% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Mar 29Independent Chairman of the Board recently sold ₪303k worth of stockOn the 21st of March, Kevin Rakin sold around 10k shares on-market at roughly ₪30.28 per share. This was the largest sale by an insider in the last 3 months. Kevin has been a seller over the last 12 months, reducing personal holdings by ₪1.7m.Reported Earnings • Jan 12First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: US$0.21 loss per share (up from US$0.23 loss in 1Q 2021). Net loss: US$7.89m (loss widened 42% from 1Q 2021). Revenue missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 2.2%, compared to a 22% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$0.78 loss per share (down from US$0.56 loss in FY 2020). Net loss: US$22.2m (loss widened 93% from FY 2020). Revenue missed analyst estimates by 9.2%. Over the next year, revenue is forecast to stay flat compared to a 23% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Sep 22Independent Chairman of the Board recently sold ₪1.4m worth of stockOn the 16th of September, Kevin Rakin sold around 21k shares on-market at roughly ₪67.43 per share. This was the largest sale by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months.Executive Departure • Sep 03Independent Director Xiaoming Gao has left the companyOn the 30th of August, Xiaoming Gao's tenure as Independent Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Xiaoming's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.42 years.Reported Earnings • Jul 16Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.098 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$5.21m (loss widened 128% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.Executive Departure • Jul 13CFO, Treasurer & Secretary Avraham Gabay has left the companyOn the 5th of July, Avraham Gabay's tenure as CFO, Treasurer & Secretary ended after 2.1 years in the role. We don't have any record of a personal shareholding under Avraham's name. Avraham is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 10.00 years.Reported Earnings • Apr 16Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$4.61m (loss widened 25% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Feb 17New 90-day high: ₪36.50The company is up 326% from its price of ₪8.57 on 19 November 2020. The Israeli market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 20% over the same period.Is New 90 Day High Low • Jan 25New 90-day high: ₪21.96The company is up 160% from its price of ₪8.44 on 27 October 2020. The Israeli market is up 25% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Analyst Estimate Surprise Post Earnings • Jan 19Revenue beats expectationsRevenue exceeded analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 29%, compared to a 240% growth forecast for the Pharmaceuticals industry in Israel.Reported Earnings • Jan 15First quarter 2021 earnings released: US$0.23 loss per shareFirst quarter 2021 results: Net loss: US$5.57m (loss widened 119% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Nov 30New 90-day high: ₪16.00The company is up 38% from its price of ₪11.56 on 01 September 2020. The Israeli market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪149 per share.Reported Earnings • Nov 25Full year 2020 earnings released: US$0.56 loss per shareFull year 2020 results: Net loss: US$11.5m (loss narrowed 20% from FY 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Nov 25Revenue misses expectationsRevenue missed analyst estimates by 31%. Over the next year, revenue is forecast to grow 32%, compared to a 77% growth forecast for the Pharmaceuticals industry in Israel.Is New 90 Day High Low • Oct 26New 90-day low: ₪8.64The company is down 35% from its price of ₪13.33 on 28 July 2020. The Israeli market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪141 per share.Is New 90 Day High Low • Sep 30New 90-day low: ₪9.45The company is down 20% from its price of ₪11.81 on 02 July 2020. The Israeli market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪152 per share. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Oramed Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TASE:ORMP - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026N/A109-9-9N/A12/31/2025263-9-9N/A9/30/2025244-11-11N/A6/30/20252-24-16-16N/A3/31/20252-28-10-10N/A12/31/2024N/A-19-8-8N/A9/30/2024N/A4-8-8N/A6/30/2024N/A21-2-2N/A3/31/2024110-6-6N/A12/31/202316-11-10N/A9/30/20232-16-17-17N/A6/30/20233-20-19-18N/A3/31/20233-30-25-24N/A12/31/20223-37-28-28N/A9/30/20223-46-39-39N/A6/30/20223-46-43-43N/A3/31/20223-40-39-39N/A12/31/20213-35-33-33N/A11/30/20213-25-22-22N/A8/31/20213-22-22-21N/A5/31/20213-18-18-17N/A2/28/20213-15-16-15N/A12/31/20203-22-26-25N/A11/30/20203-15-16-16N/A8/31/20203-12-13-12N/A5/31/20203-11-13-13N/A2/29/20203-13N/A-14N/A11/30/20193-13N/A-12N/A8/31/20193-14N/A-13N/A5/31/20193-15N/A-14N/A2/28/20193-15N/A-14N/A11/30/20183-14N/A-16N/A8/31/20182-13N/A-15N/A5/31/20182-12N/A-12N/A2/28/20182-10N/A-11N/A11/30/20172-10N/A-10N/A8/31/20172-10N/A-6N/A5/31/20172-13N/A3N/A2/28/20172-13N/A3N/A11/30/20161-11N/A8N/A8/31/20161-11N/A5N/A5/31/20160-8N/A-3N/A2/29/20160-8N/A-2N/A11/30/2015N/A-8N/A-6N/A8/31/2015N/A-7N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ORMPの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ORMPの収益がIL市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ORMPの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ORMPの収益がIL市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ORMPの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ORMPの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 15:07終値2026/05/20 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oramed Pharmaceuticals Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Andrew D'SilvaB. Riley Securities, Inc.Edward NashCanaccord GenuityRobert LeBoyerLadenburg Thalmann & Company1 その他のアナリストを表示
お知らせ • May 17Oramed Pharmaceuticals Inc. announced delayed 10-Q filingOn 05/15/2026, Oramed Pharmaceuticals Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Mar 29New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 189% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (189% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (US$2.0m revenue).
お知らせ • Mar 26Lifeward Ltd. (NasdaqCM:LFWD) completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP).Lifeward Ltd. (NasdaqCM:LFWD) entered into a share purchase agreement to acquire Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) on January 12, 2026. At closing, the Company will issue ordinary shares and pre-funded warrants to Oramed Pharmaceuticals, Inc. in an amount representing 49.99% of the Company’s fully diluted equity capitalization, subject to certain adjustments and ownership limitations. The number of ordinary shares issued at closing is capped at 45% of Lifeward’s outstanding ordinary shares, with the balance issued in the form of pre-funded warrants. Approximately 5% of the equity consideration will be held back in the form of pre-funded warrants for indemnification purposes and released after 12 months, subject to claims. In addition, the Company will issue transaction warrants to purchase ordinary shares, with the number of warrants determined by dividing Lifeward’s net cash at closing by an exercise price of $0.45 per share. As further consideration, Lifeward agreed to make contingent quarterly revenue-sharing payments equal to 4% of net revenue from sales of ReWalk Personal Exoskeleton products and related warranties. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, registration statement effectiveness (S-4 / F-4), lock-up agreement and listing / approval of new shares on stock exchange. The transaction has received unanimous approval from Lifeward’s board of directors. The transaction is contingent upon closing conditions. As of March 12, 2026, Lifeward Ltd. shareholders approved the transaction. Rachael M. Bushey and Jennifer Porter of Goodwin Procter LLP acted as legal advisor for Lifeward Ltd. Aaron M. Lampert and Ephraim P. Friedman of Goldfarb Seligman & Co. acted as legal advisor for Lifeward Ltd. Rick A. Werner, Alla Digilova, and Simin Sun of Haynes and Boone, LLP acted as legal advisor for Oramed Pharmaceuticals Inc. Lifeward Ltd. (NasdaqCM:LFWD) completed the acquisition of Oratech Pharma, Inc. from Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) on March 25, 2026. At closing, Lifeward issued an aggregate 2,256,476 shares of its ordinary shares and pre-funded warrants. Lifeward also issued 1,296,296 warrants to purchase Oratech Pharma's ordinary shares.
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₪10.58, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 19% over the past three years.
お知らせ • Jan 08Oramed Pharmaceuticals Inc. Approves Cash Dividend Payable on January 26, 2026Oramed Pharmaceuticals Inc.'s Board of Directors approved a cash dividend payment of $0.25 per share. The dividend will have an ex-dividend date of January 16, 2026, with disbursement scheduled for January 26, 2026. The dividend is expected to result in an aggregate distribution of approximately $10.5 million based on the current number of shares outstanding. The dividend will be funded with surplus capital.
お知らせ • Jan 01Oramed Pharmaceuticals Inc. Announces Resignation of Leonard Sank from the Board, Effective as of January 1, 2026On December 31, 2025, the board of directors (the “Board”) of Oramed Pharmaceuticals Inc. (the “Company”) received notice of Leonard Sank’s intention to resign from the Board, effective as of January 1, 2026. Mr. Sank’s resignation did not result from any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Sank served 18 years at the Company.
Valuation Update With 7 Day Price Move • Dec 14Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₪10.33, the stock trades at a trailing P/E ratio of 2.8x. Average forward P/E is 20x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 62% over the past three years.
New Risk • Nov 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (135% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Revenue is less than US$5m (US$2.0m revenue). Market cap is less than US$100m (₪324.5m market cap, or US$99.1m).
お知らせ • Nov 18Oramed Pharmaceuticals Inc. Declares Dividend Distribution of Common Stock, Payable on November 27, 2025The Board of Directors of Oramed Pharmaceuticals Inc. announced that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company. The dividend distribution will be payable on November 27, 2025, to stockholders of record as of the close of business on November 27, 2025.
お知らせ • Jul 17Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 19, 2025Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 19, 2025. Location: proskauer rose llp, one boca place, 2255 glades road, suite 421 atrium, fl 33431-7360, boca raton United States
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Member of Scientific Advisory Board Anne Peters was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • Apr 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$2.8m net loss next year). Market cap is less than US$100m (₪321.2m market cap, or US$85.8m).
New Risk • Mar 29New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$19m Forecast net loss in 1 year: US$4.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (US$4.7m net loss next year). Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₪329.4m market cap, or US$89.1m).
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₪9.16, the stock trades at a trailing P/E ratio of 23.2x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 69% over the past three years.
New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Israeli stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 104% per year for the foreseeable future. High level of non-cash earnings (40% accrual ratio). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (5.8% average weekly change).
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₪9.34, the stock trades at a trailing P/E ratio of 23.5x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 75% over the past three years.
New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 188% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings are forecast to decline by an average of 198% per year for the foreseeable future. High level of non-cash earnings (188% accrual ratio). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪348.7m market cap, or US$95.1m).
New Risk • Jul 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪371.5m (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.7% average weekly change). Earnings are forecast to decline by an average of 169% per year for the foreseeable future. Revenue is less than US$1m (US$674k revenue). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₪371.5m market cap, or US$98.7m).
Valuation Update With 7 Day Price Move • Jun 27Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₪9.79, the stock trades at a trailing P/E ratio of 10x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total loss to shareholders of 77% over the past three years.
お知らせ • Jun 27Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces a share repurchase program. Under the program, the company will repurchase up to $20 million worth of its shares. The program will expired in 12 months.
お知らせ • Jun 22Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024. Location: 20 mamilla avenue, israel 9414904, jerusalem Israel
お知らせ • Jun 13+ 1 more updateOramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024On June 6, 2024, Oramed Pharmaceuticals Inc. appointed Mr. Avraham Gabay to serve as Treasurer and Secretary of the Company, effective as of June 18, 2024. Prior to his appointment, Mr. Gabay served as interim chief financial officer of BiomX Inc. since 2023. From 2021 until 2023, Mr. Gabay served as the chief financial officer at Oravax Inc., a 63% owned subsidiary of the Company. From 2019 until 2021, Mr. Gabay was the chief financial officer of the Company. From 2015 to 2019, Mr. Gabay served as VP Finance at Orcam Technologies Ltd. From 2014 to 2015, Mr. Gabay provided economic services in the advisory department of KPMG Israel, a certified public accounting firm, and from 2013 to 2014, he worked in the tax department of the law firm Gornitzky & Co. In addition, Mr. Gabay serves as a director on the board of Iintoo Ltd. Mr. Gabay holds a bachelor’s degree in law and accounting (magna cum-laude) from Tel-Aviv University and is a certified public accountant in Israel and a member of the Israeli Bar Association.
New Risk • May 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 95% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings are forecast to decline by an average of 95% per year for the foreseeable future. Revenue is less than US$1m (US$674k revenue). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₪345.9m market cap, or US$93.4m).
Reported Earnings • May 12First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)First quarter 2024 results: EPS: US$0.038 (up from US$0.085 loss in 1Q 2023). Net income: US$1.54m (up US$4.93m from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
New Risk • Apr 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪369.9m (US$98.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (US$1.3m revenue). Market cap is less than US$100m (₪369.9m market cap, or US$98.1m).
お知らせ • Mar 19Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: COMMON STOCK Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Mar 07Full year 2023 earnings released: EPS: US$0.14 (vs US$0.94 loss in FY 2022)Full year 2023 results: EPS: US$0.14 (up from US$0.94 loss in FY 2022). Net income: US$5.53m (up US$42.1m from FY 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
New Risk • Jan 31New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.2% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$11m net loss next year). Shareholders have been diluted in the past year (3.1% increase in shares outstanding). Revenue is less than US$5m (US$2.0m revenue).
Board Change • Jan 23Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 5 highly experienced directors. Member of Scientific Advisory Board Jay Skyler was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Dec 19Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024On December 18, 2023, Oramed Pharmaceuticals Inc. (Company) increased the size of its Board of Directors by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024. The Board has not yet taken action to appoint Dr. Aghion to any committees of the Board. Dr. Daniel Aghion, age 42, is a neurosurgeon at Memorial Neuroscience Institute in Florida since 2016, where he treats patients with a wide array of spine disorders, including severe degenerative spine diseases, spine trauma, cancer in the spine, spine tumors, peripheral nerve surgery and more. Dr. Aghion holds a Bachelor's of Science degree from the University of Michigan and an MD from the Sackler School of Medicine at Tel Aviv University. He completed his residency at Rhode Island Hospital in 2015, and a complex spine fellowship at Johns Hopkins University in Baltimore in 2016.
Reported Earnings • Nov 11Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)Third quarter 2023 results: US$0.08 loss per share (improved from US$0.18 loss in 3Q 2022). Net loss: US$3.22m (loss narrowed 54% from 3Q 2022). Revenue is expected to decline by 70% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Asia are expected to grow by 11%. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year.
New Risk • Oct 05New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₪357.4m (US$93.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$47m net loss in 3 years). Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Revenue is less than US$5m (US$2.7m revenue). Market cap is less than US$100m (₪357.4m market cap, or US$93.0m).
Reported Earnings • Aug 11Second quarter 2023 earnings released: US$0.03 loss per share (vs US$0.27 loss in 2Q 2022)Second quarter 2023 results: US$0.03 loss per share (improved from US$0.27 loss in 2Q 2022). Net loss: US$1.19m (loss narrowed 89% from 2Q 2022). Revenue is expected to decline by 84% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Asia are expected to grow by 9.8%. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 09Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million on August 4, 2023. Oramed Pharmaceuticals Inc. entered into a Stalking Horse Agreement to acquire a 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. on August 8, 2023. Oramed to purchase 59,726,737 shares of common stock of Scilex and 29,057,096 shares of Series A preferred stock of Scilex under the transaction. As a part of consideration, Oramed will provide a non-amortizing super-priority debtor-in-possession term loan financing facility in an aggregate principal amount of $100 million (the “Replacement DIP Facility”) and remaining consideration in cash. Oramed Pharmaceuticals Inc. will receive a a break-up fee in the amount of $3,412,500, in case of termmination. Oramed will be capitalized with sufficient debt and equity capital to fund the cash portion of the Purchase Price. Term Sheet is subject to a final definitive documentation to be negotiated in good faith between the parties, uthorization and approval by the United States Bankruptcy Court for the Southern District of Texas,all HSR filing and waiting periods applicable to the Sale shall have expired or been terminated, all other governmental and regulatory approvals, if any, shall have been obtained, parties shall have entered into a new Registration Rights Agreement, approval of board of directors of Scilex and satisfaction or waiver of the other Closing Conditions. The proposed transaction will not be subject to a financing contingency. The stalking horse agreement with Oramed is subject to an auction and the submission of higher or otherwise better offers. Any parties interested in bidding for the Scilex Stock should email Sorrento's investment banker (Moelis & Company LLC) as soon as possible to indicate their interest and discuss required bid materials. To the extent Sorrento receives any qualified bids that are higher or otherwise better than Oramed's bid by August 11, 2023, at 5:00 p.m. (ET), Sorrento will hold an auction for the Scilex Stock on August 14, 2023. The U.S. Bankruptcy Court for the Southern District of Texas (the "Bankruptcy Court") approved the transaction on August 8, 2023. Transaction is expected to be completed by or before September 15, 2023. Latham & Watkins LLP and Jackson Walker LLP are serving as legal counsel to Sorrento. M3 Partners is serving as restructuring advisor. Moelis & Company LLC is serving as financial advisor and investment banker. H.C. Wainwright & Co. acted as financial and capital markets advisor to Oramed.
お知らせ • Jul 12Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023, at 16:00 Israel Standard Time. Location: 20 Mamilla Avenue Jerusalem Israel Agenda: To consider and re-elect six directors of the Company to hold office until next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal; to consider and ratify the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited as the independent registered public accounting firm of the Company for the 2023 fiscal year; and to transact any other business as may properly come before the Annual Meeting or any adjournments thereof.
Reported Earnings • May 13First quarter 2023 earnings released: US$0.085 loss per share (vs US$0.27 loss in 1Q 2022)First quarter 2023 results: US$0.085 loss per share (improved from US$0.27 loss in 1Q 2022). Net loss: US$3.40m (loss narrowed 67% from 1Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Apr 06Independent Director recently bought ₪70k worth of stockOn the 4th of April, Arie Mayer bought around 9k shares on-market at roughly ₪7.94 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₪729k. Insiders have collectively bought ₪406k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Mar 16Independent Director recently bought ₪513k worth of stockOn the 14th of March, Yadin Rozov bought around 70k shares on-market at roughly ₪7.33 per share. This transaction increased Yadin's direct individual holding by 4x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₪211k more in shares than they have sold in the last 12 months.
Reported Earnings • Mar 08Full year 2022 earnings released: US$0.94 loss per share (vs US$0.94 loss in FY 2021)Full year 2022 results: US$0.94 loss per share. Net loss: US$36.6m (loss widened 4.4% from FY 2021). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.
お知らせ • Jan 12Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 DiabetesOramed Pharmaceuticals Inc. announced top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents. The ORA-D-013-1 trial did not meet its primary endpoint, which compared the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by the mean change from baseline in A1C at 26 weeks. The trial also did not meet its secondary endpoint, which assessed the mean change from baseline in fasting plasma glucose at 26 weeks. There were no serious drug-related adverse events. Therefore, Oramed expects to discontinue its oral insulin clinical activities for T2D. Additional Information About the ORA-D-013-1 Phase 3 Clinical Trial: In the ORA-D-013-1 trial, patients were randomized 2:2:1:1 into four groups: 8 mg dosed once-daily; 8 mg dosed twice-daily; placebo dosed once-daily; and placebo dosed twice-daily. Patients completed an initial 21-day Screening Period, followed by a 26-week Double-Blind Treatment Period.
お知らせ • Jan 05Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of DiabetesOramed Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Chief Scientific Officer & Director Miriam Kidron is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 12Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)Third quarter 2022 results: US$0.18 loss per share. Net loss: US$7.06m (loss widened 3.0% from 3Q 2021). Revenue is forecast to grow 86% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia.
Reported Earnings • Aug 11Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 2Q 2021)Second quarter 2022 results: US$0.27 loss per share (down from US$0.17 loss in 2Q 2021). Net loss: US$10.5m (loss widened 102% from 2Q 2021). Over the next year, revenue is forecast to grow 6.4%, compared to a 24% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 38% per year, which means it is well ahead of earnings.
Board Change • Jul 15High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 2 experienced directors. 5 highly experienced directors. Chief Scientific Officer & Director Miriam Kidron is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • May 14First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 1Q 2021)First quarter 2022 results: US$0.27 loss per share (down from US$0.17 loss in 1Q 2021). Net loss: US$10.4m (loss widened 126% from 1Q 2021). Over the next year, revenue is forecast to grow 2.5%, compared to a 23% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 02Full year 2021 earnings released: US$0.94 loss per share (vs US$0.90 loss in FY 2020)Full year 2021 results: US$0.94 loss per share (down from US$0.90 loss in FY 2020). Net loss: US$35.0m (loss widened 59% from FY 2020). Over the next year, revenue is forecast to grow 1.4%, compared to a 21% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Mar 29Independent Chairman of the Board recently sold ₪303k worth of stockOn the 21st of March, Kevin Rakin sold around 10k shares on-market at roughly ₪30.28 per share. This was the largest sale by an insider in the last 3 months. Kevin has been a seller over the last 12 months, reducing personal holdings by ₪1.7m.
Reported Earnings • Jan 12First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: US$0.21 loss per share (up from US$0.23 loss in 1Q 2021). Net loss: US$7.89m (loss widened 42% from 1Q 2021). Revenue missed analyst estimates by 3.7%. Over the next year, revenue is forecast to grow 2.2%, compared to a 22% growth forecast for the industry in Israel. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 25Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: US$0.78 loss per share (down from US$0.56 loss in FY 2020). Net loss: US$22.2m (loss widened 93% from FY 2020). Revenue missed analyst estimates by 9.2%. Over the next year, revenue is forecast to stay flat compared to a 23% growth forecast for the pharmaceuticals industry in Israel. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Sep 22Independent Chairman of the Board recently sold ₪1.4m worth of stockOn the 16th of September, Kevin Rakin sold around 21k shares on-market at roughly ₪67.43 per share. This was the largest sale by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months.
Executive Departure • Sep 03Independent Director Xiaoming Gao has left the companyOn the 30th of August, Xiaoming Gao's tenure as Independent Director ended after 2.2 years in the role. We don't have any record of a personal shareholding under Xiaoming's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 3.42 years.
Reported Earnings • Jul 16Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.098 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$5.21m (loss widened 128% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth.
Executive Departure • Jul 13CFO, Treasurer & Secretary Avraham Gabay has left the companyOn the 5th of July, Avraham Gabay's tenure as CFO, Treasurer & Secretary ended after 2.1 years in the role. We don't have any record of a personal shareholding under Avraham's name. Avraham is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 10.00 years.
Reported Earnings • Apr 16Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2020)Second quarter 2021 results: Net loss: US$4.61m (loss widened 25% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Feb 17New 90-day high: ₪36.50The company is up 326% from its price of ₪8.57 on 19 November 2020. The Israeli market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 20% over the same period.
Is New 90 Day High Low • Jan 25New 90-day high: ₪21.96The company is up 160% from its price of ₪8.44 on 27 October 2020. The Israeli market is up 25% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Analyst Estimate Surprise Post Earnings • Jan 19Revenue beats expectationsRevenue exceeded analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 29%, compared to a 240% growth forecast for the Pharmaceuticals industry in Israel.
Reported Earnings • Jan 15First quarter 2021 earnings released: US$0.23 loss per shareFirst quarter 2021 results: Net loss: US$5.57m (loss widened 119% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Nov 30New 90-day high: ₪16.00The company is up 38% from its price of ₪11.56 on 01 September 2020. The Israeli market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪149 per share.
Reported Earnings • Nov 25Full year 2020 earnings released: US$0.56 loss per shareFull year 2020 results: Net loss: US$11.5m (loss narrowed 20% from FY 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Nov 25Revenue misses expectationsRevenue missed analyst estimates by 31%. Over the next year, revenue is forecast to grow 32%, compared to a 77% growth forecast for the Pharmaceuticals industry in Israel.
Is New 90 Day High Low • Oct 26New 90-day low: ₪8.64The company is down 35% from its price of ₪13.33 on 28 July 2020. The Israeli market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪141 per share.
Is New 90 Day High Low • Sep 30New 90-day low: ₪9.45The company is down 20% from its price of ₪11.81 on 02 July 2020. The Israeli market is up 2.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 25% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₪152 per share.